No noticeNo retraction, correction or concern found when last checked on Nov 14, 2026.
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom
Catherine Hyams, Robert Challen, Robin Marlow and 71 more
The Lancet Regional Health - Europe · 2023 · CC BY
doi:10.1016/j.lanepe.2022.100556 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background. There is an urgent public health need to evaluate disease severity in adults hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist assessing severity of disease in adults hospitalised with Omicron SARS-CoV-2 infections, and to what extent patient-factors, including vaccination, age, frailty and pre-existing disease, affect variant-dependent disease severity.
Methods. A prospective cohort study of adults (≥18 years of age) hospitalised with acute lower respiratory tract disease at acute care hospitals in Bristol, UK conducted over 10-months. Delta or Omicron SARS-CoV-2 infection was defined by positive SARS-CoV-2 PCR and variant identification or inferred by dominant circulating variant. We constructed adjusted regression analyses to assess disease severity using three different measures: FiO2 >28% (fraction inspired oxygen), World Health Organization (WHO) outcome score >5 (assessing need for ventilatory support), and hospital length of stay (LOS) >3 days following admission for Omicron or Delta infection.
Findings. Independent of other variables, including vaccination, Omicron variant infection in hospitalised adults was associated with lower severity than Delta. Risk reductions were 58%, 67%, and 16% for supplementary oxygen with >28% FiO2 [Relative Risk (RR) = 0.42 (95%CI: 0.34–0.52), P < 0.001], WHO outcome score >5 [RR = 0.33 (95%CI: 0.21–0.50), P < 0.001], and to have had a LOS > 3 days [RR = 0.84 (95%CI: 0.76–0.92), P < 0.001]. Younger age and vaccination with two or three doses were also independently associated with lower COVID-19 severity.
Interpretation. We provide reassuring evidence that Omicron infection results in less serious adverse outcomes than Delta in hospitalised patients. Despite lower severity relative to Delta, Omicron infection still resulted in substantial patient and public health burden and an increased admission rate of older patients with Omicron which counteracts some of the benefit arising from less severe disease.
Funding. AvonCAP is an investigator-led project funded under a collaborative agreement by Pfizer.
Abstract licence: CC BY-NC
References34
- 1.
Challen R., Dyson L., Overton C.E., et al. Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England. medRxiv. 2021.
Not in our library10.1101/2021.06.05.21258365 (opens in a new tab)
- 2.
Government U. Coronavirus (COVID-19) in the UK. 2022.
Not in our library
- 3.
UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 36. 2022.
Not in our library
- 4.
Wang P., Nair M.S., Liu L., et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 2021;593(7857):130-135.
Not in our library10.1038/s41586-021-03398-2 (opens in a new tab)
- 5.
Liu Y., Liu J., Xia H., et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384(15):1466-1468.
Not in our library10.1056/nejmc2102017 (opens in a new tab)
- 6.
Nemet I., Kliker L., Lustig Y., et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med. 2021;386(5):492-494.
Not in our library10.1056/nejmc2119358 (opens in a new tab)
- 7.
Schmidt F., Muecksch F., Weisblum Y., et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med. 2021;386(6):599-601.
Not in our library10.1056/nejmc2119641 (opens in a new tab)
- 8.
Ferguson N., Ghani A., Hinsley W., Volz E. 2022.
Not in our library
- 9.
- 10.
UKHSA. 2022.
Not in our library
- 11.
Lauring A.S., Tenforde M.W., Chappell J.D., et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376.
Not in our library10.1136/bmj-2021-069761 (opens in a new tab)
- 12.
Ferdinands J., Rao S., Dixon B., et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255-263.
Not in our library10.15585/mmwr.mm7107e2 (opens in a new tab)
- 13.
Thompson M., Natarajan K., Sa I., et al. Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:139-145.
Not in our library10.15585/mmwr.mm7104e3 (opens in a new tab)
- 14.
- 15.
Kirsebom F.C.M., Andrews N., Stowe J., et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis. 2022;22(7):931-933.
Not in our library10.1016/s1473-3099(22)00309-7 (opens in a new tab)
- 16.
UKHSA UHSA. COVID-19 vaccine surveillance report: week 19. 2022.
Not in our library
- 17.
- 18.
Bager P., Wohlfahrt J., Fonager J., et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21(11):1507-1517.
Not in our library10.1016/s1473-3099(21)00290-5 (opens in a new tab)
- 19.
Strasser Z., Hadavand A., Murphy S., Estiri H. SARS-CoV-2 omicron variant is as deadly as previous waves after adjusting for vaccinations, demographics, and comorbidities. Research Square. 2022.
Not in our library10.21203/rs.3.rs-1601788/v1 (opens in a new tab)
- 20.
Hyams C., Marlow R., Maseko Z., et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539-1548.
Not in our library10.1016/s1473-3099(21)00330-3 (opens in a new tab)
- 21.
Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
Not in our library10.1016/j.jbi.2008.08.010 (opens in a new tab)
- 22.
Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Not in our library10.1016/0021-9681(87)90171-8 (opens in a new tab)
- 23.
- 24.
Rockwood K., Song X., MacKnight C., et al. A global clinical measure of fitness and frailty in elderly people. Can Med Assoc J. 2005;173(5):489-495.
Not in our library10.1503/cmaj.050051 (opens in a new tab)
- 25.
Physicians RCo. 2017.
Not in our library
- 26.
UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 33, 2021.
Not in our library
- 27.
Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e197.
Not in our library10.1016/s1473-3099(20)30483-7 (opens in a new tab)
- 28.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706.
Not in our library10.1093/aje/kwh090 (opens in a new tab)
- 29.
van Buuren S., Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Software. 2011;45(3):1-67.
Not in our library
- 30.
Team RC. 2014.
Not in our library
- 31.
Zeileis A., Köll S., Graham N. Various versatile variances: an object-oriented implementation of clustered covariances in R. J Stat Software. 2020;95(1):1-36.
Not in our library
- 32.
Lewnard J.A., Hong V.X., Patel M.M., Kahn R., Lipsitch M., Tartof S.Y. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. Nat Med. 2022;28(9):1933-1943.
Not in our library10.1038/s41591-022-01887-z (opens in a new tab)
- 33.
Van Goethem N., Chung P.Y., Meurisse M., et al. Clinical severity of SARS-CoV-2 omicron variant compared with delta among hospitalized COVID-19 patients in Belgium during Autumn and Winter season 2021–2022. Viruses. 2022;14(6):1297.
Not in our library10.3390/v14061297 (opens in a new tab)
- 34.
Wheelock A., Miraldo M., Thomson A., Vincent C., Sevdalis N. Evaluating the importance of policy amenable factors in explaining influenza vaccination: a cross-sectional multinational study. BMJ Open. 2017;7(7).
Not in our library10.1136/bmjopen-2016-014668 (opens in a new tab)
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.